Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/42710
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLongui, Carlos Alberto
dc.contributor.authorKochi, Cristiane
dc.contributor.authorCalliari, Luis Eduardo Procopio [UNIFESP]
dc.contributor.authorModkovski, Maria Barcellos Rosa
dc.contributor.authorSoares, Marisa
dc.contributor.authorAlves, Erica Ferreira
dc.contributor.authorPrudente, Fernanda Vilas Boas
dc.contributor.authorMonte, Osmar
dc.date.accessioned2018-06-15T14:00:11Z-
dc.date.available2018-06-15T14:00:11Z-
dc.date.issued2011-11-01
dc.identifierhttp://dx.doi.org/10.1590/S0004-27302011000800023
dc.identifier.citationArquivos Brasileiros De Endocrinologia E Metabologia. Rio De Janeiro, Rj: Sbem-soc Brasil Endocrinologia & Metabologia, v. 55, n. 8, p. 661-664, 2011.
dc.identifier.issn0004-2730
dc.identifier.urihttp://repositorio.unifesp.br/11600/42710-
dc.description.abstractIntroduction: Intrinsic limitations of glucocorticoid therapy in patients with congenital adrenal hyperplasia (CAH) determine frequent loss in final height. The association of secondary central precocious puberty and early epiphyseal fusion is also frequent. In these conditions, GnRHa treatment alone or in combination with GH has been indicated. Objectives: This is a retrospective study, describing the estatural findings of CAH patients with significant decrease in height prediction, who were submitted to combined GH plus GnRHa therapy up to near-final height. Subjects and methods: We studied 13 patients, eight females and five males, eight with the classical and five with the nonclassical form of the disorder. Treatment with hydrocortisone (10-20 mg/m(2)/day) or prednisolone (3-6 mg/kg/day) was associated with GnRHa (3.75 mg/months) for 4.0 (1.5) years, and GH (0.05 mg/kg/day) for 3.6 (1.4) years. Results: Stature standard deviation score for bone age improved significantly after GH treatment, becoming similar to target height at the end of the second year of GH treatment. Conclusion: We conclude that combined GH plus GnRHa therapy can be useful in a subset of CAH patients with significant reduction of predicted final height associated with poor hormonal control and central precocious puberty. Arq Bras Endocrinol Metab. 2011;55(8):661-4en
dc.format.extent661-664
dc.language.isoeng
dc.publisherSbem-soc Brasil Endocrinologia & Metabologia
dc.relation.ispartofArquivos Brasileiros De Endocrinologia E Metabologia
dc.rightsAcesso aberto
dc.subjectGHen
dc.subjectGnRHaen
dc.subjectcongenital adrenal hyperplasiaen
dc.subjectheighten
dc.subjectgrowth recoveryen
dc.titleNear-final height in patients with congenital adrenal hyperplasia treated with combined therapy using GH and GnRHaen
dc.title.alternativeAltura quase normal em pacientes com hiperplasia adrenal congênita tratados com a combinação de GH e GnRHapt
dc.typeArtigo
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.description.affiliationISCMSP, Dept Pediat, Pediat Endocrinol Unit, Sao Paulo, Brazil
dc.identifier.fileS0004-27302011000800023.pdf
dc.identifier.scieloS0004-27302011000800023
dc.identifier.doi10.1590/S0004-27302011000800023
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000298885900023
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.